Bispecifics: Synergy That Can Be Modeled, Not Easily Verified
A case study of a α4β7 × TL1A bispecific
Multispecific antibodies have been touted as a great leap forward in the treatment of I&I diseases, where remission rates are not high to begin with and such remission is not always durable.
As multi‑specific antibodies move from concept to clinic, the ecosystem around trial design, PD readouts, and safety surveillance is being rewritten. A useful case s…
